Submit a Letter to the Editor for:
Matthew J. Flick, XinLi Du, David P. Witte, Markéta Jiroušková, Dmitry A. Soloviev, Steven J. Busuttil, Edward F. Plow, Jay L. Degen
J Clin Invest. 2004;
113(11):1596
doi:10.1172/JCI20741
Abstract |
Full text
|
PDF
|
Supplemental material

T
he leukocyte integrin αMβ2/Mac-1
appears to support the inflammatory response through multiple ligands, but local
engagement of fibrin(ogen) may be particularly important for leukocyte function.
To define the biological significance of
fibrin(ogen)-αMβ2 interaction
in vivo, gene-targeted mice were generated in which the
αMβ2-binding motif within the
fibrinogen γ chain (N390RLSIGE396) was
converted to a series of alanine residues. Mice carrying the Fibγ
390–396A
allele maintained normal levels of fibrinogen, retained normal clotting
function, supported platelet aggregation, and never developed spontaneous
hemorrhagic events. However, the mutant fibrinogen failed to support
αMβ2-mediated adhesion of
primary neutrophils, macrophages, and
αMβ2-expressing cell lines.
The elimination of the
αMβ2-binding motif on fibrin(ogen)
severely compromised the inflammatory response in vivo as evidenced by a
dramatic impediment in leukocyte clearance of Staphylococcus
aureus inoculated into the peritoneal cavity. This defect in bacterial
clearance was due not to diminished leukocyte trafficking but rather to a
failure to fully implement antimicrobial functions. These studies definitively
demonstrate that fibrin(ogen) is a physiologically relevant ligand for
αMβ2, integrin engagement of
fibrin(ogen) is critical to leukocyte function and innate immunity in vivo, and
the biological importance of fibrinogen in regulating the inflammatory response
can be appreciated outside of any alteration in clotting function.
Guidelines:
The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. All accepted letters will be posted on our website within one week of acceptance. The Editors reserve the right to edit any letter for length, content, and clarity. Authors of all accepted letters will be asked to preview any changes. Authors will be notified by e-mail if their letters were not accepted. As this is a final decision, no appeals will be considered.
Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML, if you wish. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editor directly at editors@the-jci.org.